| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/09/2014 | EP2714661A1 Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists |
| 04/09/2014 | EP2714660A1 Neprilysin inhibitors |
| 04/09/2014 | EP2714658A1 Novel hybrid cholinesterase inhibitors |
| 04/09/2014 | EP2714657A1 Morpholino compounds, uses and methods |
| 04/09/2014 | EP2714654A1 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group |
| 04/09/2014 | EP2714651A1 N,n-substituted guanidine compound |
| 04/09/2014 | EP2714636A1 Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars |
| 04/09/2014 | EP2714115A1 Expandable devices coated with a paclitaxel composition |
| 04/09/2014 | EP2714114A1 Expandable devices coated with a rapamycin composition |
| 04/09/2014 | EP2714096A1 Compositions and methods for transport across the blood brain barrier |
| 04/09/2014 | EP2714089A1 Compositions and methods for efficacious and safe delivery of sirna using specific chitosan-based nanocomplexes |
| 04/09/2014 | EP2714086A1 Polyphenol composition for preventing or treating atherosclerosis |
| 04/09/2014 | EP2714085A1 Anti-inflammatory composition |
| 04/09/2014 | EP2714054A2 Method, composition, and articles for improving joint lubrication |
| 04/09/2014 | EP2714053A1 Opsonized beta-glucan preparations and methods |
| 04/09/2014 | EP2714052A1 Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents |
| 04/09/2014 | EP2714051A1 A method of managing hypercortisolemia, headache disorders, neuropathic pain and related disorders |
| 04/09/2014 | EP2714050A1 Scyllo-inositol for the treatment of behavioral and psychiatric disorders |
| 04/09/2014 | EP2714049A1 Pharmaceutical composition comprising dapagliflozin and cyclodextrin |
| 04/09/2014 | EP2714048A1 SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF |
| 04/09/2014 | EP2714047A1 Novel ticagrelor co - crystal |
| 04/09/2014 | EP2714046A1 Methods of treating mesothelioma with a pi3k inhibitor compound |
| 04/09/2014 | EP2714045A1 Pharmaceutical antiretroviral composition |
| 04/09/2014 | EP2714044A1 Composition and tablet comprising raltegravir |
| 04/09/2014 | EP2714043A1 Compositions for sequential administration of opioid receptor agonists |
| 04/09/2014 | EP2714042A1 An analgesic pharmaceutical composition for oral administration |
| 04/09/2014 | EP2714041A1 Aryloxymethyl cyclopropane derivatives as pde10 inhibitors |
| 04/09/2014 | EP2714040A1 Combinations of serotonin receptor agonists for treatment of movement disorders |
| 04/09/2014 | EP2714039A1 Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| 04/09/2014 | EP2714038A1 Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
| 04/09/2014 | EP2714037A1 Erk inhibitors for use in treating spinal muscular atrophy |
| 04/09/2014 | EP2714036A2 Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
| 04/09/2014 | EP2714035A2 Anti-viral compounds |
| 04/09/2014 | EP2714034A1 Compositions comprising antibacterial agent and tazobactam |
| 04/09/2014 | EP2714033A1 Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| 04/09/2014 | EP2714032A2 Novel diphenylmethane derivatives as sglt2 inhibitors |
| 04/09/2014 | EP2714031A1 A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck |
| 04/09/2014 | EP2714030A1 Fe(iii) 2,4-dioxo-1-carbonyl complexes for treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias |
| 04/09/2014 | EP2714029A1 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders |
| 04/09/2014 | EP2714028A1 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of visual system disorders |
| 04/09/2014 | EP2714027A1 Fatty acid amide hydrolase inhibitors for treating pain |
| 04/09/2014 | EP2714026A2 Modulation of the ubiquitin-proteasome system (ups) |
| 04/09/2014 | EP2714025A1 Clenbuterol for use in treatment of autism |
| 04/09/2014 | EP2714024A1 Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
| 04/09/2014 | EP2714023A2 Crosslinked polymer nano-assemblies and uses thereof |
| 04/09/2014 | EP2714022A1 Combination for treatment of diabetes mellitus |
| 04/09/2014 | EP2714021A1 Composition of monoterpenoids having bactericidal properties |
| 04/09/2014 | EP2714020A1 Novel treatments |
| 04/09/2014 | EP2714018A1 Transdermal therapeutic system comprising buprenorphine and an alpha-hydroxy acid |
| 04/09/2014 | EP2714016A1 Targeted delivery of retinoid compounds to the sebaceous glands |
| 04/09/2014 | EP2714011A2 Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
| 04/09/2014 | EP2714010A2 Topical pharmaceutical composition based on semifluorinated alkanes |
| 04/09/2014 | EP2714009A1 Stable liquid formulation of etanercept |
| 04/09/2014 | EP2714008A2 Pharmaceutical composition for administration to nails |
| 04/09/2014 | EP2714007A2 Ophthalmic preparation comprising a pgf2alpha analogue |
| 04/09/2014 | EP2714006A1 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
| 04/09/2014 | EP2714005A1 Nasal pharmaceutical formulation |
| 04/09/2014 | EP2713991A2 Topical wash composition for use in acne patients |
| 04/09/2014 | EP2713776A1 Antioxidant composition for the reduction of the causes of reduced male reproductive capacity |
| 04/09/2014 | EP2713775A1 Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition |
| 04/09/2014 | EP2713773A1 A composition comprising at least one alginate for use in treatment and/or prevention of overweight |
| 04/09/2014 | EP2713771A1 Composition based on ubidecarenone |
| 04/09/2014 | EP2713737A1 Novel immune system modulators |
| 04/09/2014 | EP2713736A1 Novel immune system modulators |
| 04/09/2014 | EP2713730A1 Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof |
| 04/09/2014 | EP2713729A2 Synergistic combinations of polyene fungicides and non-ribosomal peptides and related methods of use |
| 04/09/2014 | EP2713727A1 Combination of mek inhibitors and selective inhibitors of aurora a kinase |
| 04/09/2014 | EP2713725A1 Oxidatively-stabilized fats containing very long-chain omega-3 polyunsaturated fatty acids |
| 04/09/2014 | EP2713724A1 Methods of treating multiple sclerosis and preserving and/or increasing myelin content |
| 04/09/2014 | EP2713723A1 Method of determining vasoreactivity using inhaled nitric oxide |
| 04/09/2014 | EP2713722A1 Novel glp-1 receptor stabilizers and modulators |
| 04/09/2014 | CN103717736A Protein exhibiting fatty acid elongation promoting activity, gene encoding same and use thereof |
| 04/09/2014 | CN103717735A Technique for cleaving out part of poly(a) chain and/or 3'-terminal sequence of mRNA to inhibit translation reaction |
| 04/09/2014 | CN103717615A Pcsk9-binding polypeptides and methods of use |
| 04/09/2014 | CN103717609A Tricyclic inhibitors of poly(adp-ribose)polymerase |
| 04/09/2014 | CN103717607A Cefuroxime sodium crystal compound and composition powder injection thereof |
| 04/09/2014 | CN103717605A Spiro-oxindole mdm2 antagonists |
| 04/09/2014 | CN103717604A Substituted aminoimidazopyridazines |
| 04/09/2014 | CN103717602A Kinase inhibitors |
| 04/09/2014 | CN103717600A Pyrido-pyrimidine derivatives |
| 04/09/2014 | CN103717599A Indazoles |
| 04/09/2014 | CN103717597A Heterocyclic compounds as kinase inhibitors |
| 04/09/2014 | CN103717596A Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| 04/09/2014 | CN103717595A Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| 04/09/2014 | CN103717594A TRPV1 antagonists including dihydroxy substituent and uses thereof |
| 04/09/2014 | CN103717593A Compositions and methods for modulating a kinase |
| 04/09/2014 | CN103717592A Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
| 04/09/2014 | CN103717591A Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| 04/09/2014 | CN103717590A Quinazoline-7-ether compounds and methods of use |
| 04/09/2014 | CN103717589A Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| 04/09/2014 | CN103717588A Novel pyrazole derivative |
| 04/09/2014 | CN103717586A Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes |
| 04/09/2014 | CN103717583A Dibenzothiazepine derivatives and their use in the treatment of cns disorders |
| 04/09/2014 | CN103717582A Isoxazole derivatives useful as antibacterial agents |
| 04/09/2014 | CN103717576A Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
| 04/09/2014 | CN103717574A Novel compounds and compositions for the inhibition of nampt |
| 04/09/2014 | CN103717573A Amido-pyridyl ether compounds and compositions and their use against parasites |
| 04/09/2014 | CN103717232A Lixisenatide as add-on therapy to basal insulin in type 2 diabetes |
| 04/09/2014 | CN103717227A Clostridium difficile growth inhibitor |
| 04/09/2014 | CN103717225A Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) |